Intravenous-to-Subcutaneous Drug Markets

intravenous-to-subcutaneous drug markets   Intravenous-to-Subcutaneous Drug Markets  •  June 2016  •  JSC332R  • US $2,850

The number of drugs based on biologicals continues to grow at an increasingly rapid rate. Because of their physical properties and the relatively high administration volumes often required to achieve the desired therapeutic effect, the majority are developed and launched for intravenous administration. This is creating a burgeoning demand for infusion facilities, personnel and equipment. The relative complexity, costs and patient logistics associated with IV infusion relative to other routes of administration is creating interest in post-launch re-engineering of IV drugs to allow them to be administered subcutaneously. A number of technology approaches are currently being employed to accomplish this migration. By pursuing intravenous-to-subcutaneous drug markets, drug owners are finding they can achieve a number of competitive advantages.

Bar_Graph   Report Brochure (Download PDF)

Blue document    Report Order Form (Download PDF)


Intravenous-to-Subcutaneous Drug Markets – What You Will Learn

• What intravenous drugs have been strategically re-engineered for subcutaneous administration, what are the technologies being used, and what is their current market status?
• What are the therapeutic markets that are viewed as having the greatest potential for IV-to-SC migration?
• What are the major factors driving intravenous-to-subcutaneous drug re-engineering?
• How are intravenous-to-subcutaneous drugs currently aligned with drug classes and therapeutic markets?
• What intravenous drugs are currently being developed for eventual release as subcutaneously administered drugs, and what is their current status?
• What is the market impact of IV-to-SC drug migration? What will it be in 2020?
• Who are the significant players in this segment? What are their strategies? Who are their alliance partners?

Intravenous-to-Subcutaneous Drug Markets – Summary of Contents

Executive Summary

The Market Opportunity

Market Sector Dynamics
IV-to-SC Administration –The Opportunity
Intravenous-to-Subcutaneous Market Drivers
Managed Care and Healthcare Economics
Patient Sentiment
Delivery Device Innovation
Patent/Life Cycle Strategies
Competitive Landscape
Risk Factors

Intravenous-to-Subcutaneous Technology

Drug Formulation
Injection Site Modification
Delivery Device Innovation
Development Factors
Human Engineering/Ergonomics
Lyophilized Drugs/Reconstitution

IV-to-SC – Drug Product Analysis

Blood Factors
Plasma-derived Immune Inhibitors
Recombinant Immunotherapeutics

IV-to-SC – Therapeutic Sector Analysis

Platelet Inhibition
Multiple Sclerosis
Reproductive Health

Market Factors

Regulatory Issues
Collaborations and Alliances
Emerging Technologies

Company Profiles